

## [Streptokinase](#)

Statut de médicament essentiel

Section:

[12. Cardiovascular medicines 12.5. Antithrombotic medicines 12.5.2. Thrombolytic medicines](#)

Codes ATC: [B01AD01](#)

Indication

Acute myocardial infarction Code ICD11: [BA41.Z](#)

INN

Streptokinase

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

**Parenteral > General injections > IV:** 1.5 million IU in vial powder for injection

Historique des statuts LME

Ajouté pour la première fois en 1991 ([TRS 825](#))

Modifié en 1993 ([TRS 850](#))

Modifié en 2003 ([TRS 920](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Streptokinase](#)

DrugBank

[Streptokinase](#)

Résumé des preuves et recommandation du comité d'experts



The Committee reviewed an application submitted by Aventis Behring, GmbH, Marburg Germany, to remove the 100000 IU dosage form of streptokinase from the Model List. The Committee noted that the recommended standard dosage for streptokinase's main indication, the treatment of acute myocardial infarction, is 1.5 million IU. The Committee recommended that the dosage form for streptokinase be changed to: powder for injection, 1.5 million IU in vial and that the note, "For use in rare or exceptional circumstances." be removed since its value in treating acute myocardial infarction is now well established and its use is no longer reserved for exceptional situations. The Committee recommended that the dosage form for streptokinase be changed to powder for injection, 1.5 million IU in vial and that the existing footnote, "For use in rare disorders or in exceptional circumstances." be removed.